Glutathione Protocol Guide - Dosing Context, Routes & Safety

Glutathione (often written GSH) is the most abundant antioxidant your body makes on its own. It is a small protein-like molecule called a tripeptide, built from three amino acids: cysteine, glycine, and glutamate. Almost every cell makes it, and the liver makes the most.

People take glutathione for very different reasons, and the route matters a lot. The four routes studied in humans are oral capsules, liposomal or sublingual forms (designed to survive digestion), intranasal spray (studied in Parkinson's research), and intravenous (IV) infusions (used in clinics, often for skin lightening). These are not interchangeable, and the evidence behind each is different.

There is no single official glutathione dose, because it is not an FDA-approved drug for the uses people search for. What follows is dosing context from published human studies, not a recommendation. The numbers below are what researchers actually used so you can understand the research landscape.

The single most important thing to understand before any dose talk: studies disagree on whether standard oral glutathione even reaches your bloodstream in a useful way. In a 2015 six-month RCT, Richie and colleagues reported that 250 mg/day and 1,000 mg/day raised glutathione in blood, red cells, and other tissues. But a 2011 RCT by Allen and Bradley gave 500 mg twice daily for four weeks and found no change in glutathione status or oxidative-stress markers. A 1992 study gave a single 3 g dose to seven people and saw no rise in blood levels. This is why liposomal and sublingual forms exist.

Most people who take glutathione never reconstitute anything — they swallow a capsule or liposomal liquid. Reconstitution only applies to lyophilized (freeze-dried powder) research glutathione intended for injection, which is the highest-risk route and should involve a clinician.

If you are working with a powdered research vial, the math works like every other peptide. Example: a 1,200 mg vial reconstituted with 3.0 mL of bacteriostatic water gives 400 mg/mL. A 0.10 mL draw (10 units on a U-100 syringe) would then deliver 40 mg. Always confirm the actual vial label rather than assuming.

In plain English: glutathione is your cells' main cleanup molecule. It grabs onto unstable molecules called free radicals and neutralizes them before they damage cell parts. It also helps the liver tag and remove certain toxins so they can leave the body.

The technical version: glutathione donates an electron from its cysteine sulfur group to neutralize reactive oxygen species. In doing so it becomes oxidized (GSSG), then an enzyme called glutathione reductase recycles it back to the active reduced form (GSH). The ratio of GSH to GSSG is a common lab marker of how much oxidative stress a cell is under.

For skin specifically, glutathione blocks an enzyme called tyrosinase and nudges pigment cells toward making lighter pheomelanin instead of darker eumelanin. That is the mechanism behind the skin-lightening research — and also why regulators worry that lightening could reduce the skin's natural UV protection over time.

One well-established clinical fact anchors all of this: when someone overdoses on acetaminophen (Tylenol), the liver burns through its glutathione detoxifying the drug. The antidote, N-acetylcysteine (NAC), works by refilling the cysteine your liver needs to rebuild glutathione. That is real, FDA-recognized pharmacology, and it explains why cysteine supply is the rate-limiting step for making glutathione.

Oral glutathione is generally well tolerated in trials. Reported effects are usually mild: bloating, loose stools, or cramping. In the long oral skin-lightening and body-store trials, lab markers (liver enzymes, kidney values) stayed normal. Some reviews note theoretical concern that lightening skin could lower natural UV protection.

This is where the serious risks live. In one IV skin-lightening study, about 40% of participants reported abdominal cramps, 32% had deranged liver function tests, and 16% had diarrhea or tingling. Case reports describe anaphylaxis, severe systemic inflammation, acute liver injury, and one report of cardiomyopathy in a glutathione trial participant.

The biggest injectable danger is not the molecule — it is the product. In January 2019, seven patients at one clinic had reactions within minutes of an IV glutathione infusion that the FDA linked to high endotoxin levels in the powder used to compound it. Unregulated injections also carry infection risks (HIV, hepatitis) when needles or facilities are not sterile.

Sensitive-topic note: skin-lightening practices intersect with serious health, cultural, and self-image issues. If skin tone is causing distress, a dermatologist is a safer first stop than a clinic offering IV drips. This is a sensitive area; the safest information here is the information that keeps you away from unregulated injections.

Timelines depend on the goal. In oral skin-lightening RCTs, measurable melanin-index changes took about 2-4 weeks to appear and continued over 4-12 weeks. Crucially, the lightening faded after people stopped — it was not permanent.

For body-store changes, the 2015 oral RCT saw blood glutathione rise at 1, 3, and 6 months, then return to baseline within one month of stopping. So any effect appears tied to ongoing use.

Here is the honest state of the evidence, strongest to weakest. I read each of these trials directly rather than relying on supplement-brand summaries.

A 2025 systematic review found five RCTs plus one open-label study where oral glutathione at 250-500 mg/day produced a statistically significant drop in melanin index versus placebo. The effects were modest and reversible. This is the area with the most repeatable human data — and it is cosmetic, not a health cure.

A 2017 open-label pilot gave 300 mg/day oral glutathione for four months to NAFLD patients and saw ALT (a liver enzyme) drop. A 2025 review pooled three small trials (109 people total) and found consistent ALT and oxidative-stress improvements. But these are small and uncontrolled or underpowered — not proof.

Intranasal glutathione was safe and tolerable in Mischley's trials, and the high-dose group improved over baseline. But it did not beat placebo, so it cannot be called an effective treatment.

The Richie 2015 RCT said oral works; the Allen 2011 RCT and a 1992 single-dose study said it does not. This unresolved disagreement is the reason liposomal and sublingual products exist, and the reason you should be skeptical of any product promising guaranteed results.

As of May 2026: oral glutathione is sold in the United States as a dietary supplement, which means it is not reviewed or approved by the FDA as a drug for treating, curing, or preventing disease. Quality and label accuracy vary by brand, so third-party testing matters.

Injectable and IV glutathione is a different story. No injectable glutathione product is FDA-approved for skin lightening or wellness in the US. The FDA issued a June 2019 compounding alert after endotoxin-related adverse events, and the FDA Philippines issued advisory 2019-182 warning against IV glutathione for skin lightening. In some countries injectable glutathione is approved only as an add-on in cisplatin chemotherapy, not for cosmetics.

A common question is glutathione versus NAC. NAC is not glutathione — it is a cheap, well-studied precursor that supplies the cysteine your body needs to build its own glutathione. For raising glutathione indirectly, NAC has stronger pharmacology behind it (it is the hospital antidote for Tylenol overdose). For direct cosmetic pigmentation effects, oral glutathione has the dedicated skin RCTs.

Glutathione is often discussed alongside other antioxidant and skin-focused compounds. See related research references below.